Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LXEOthis companyLexeo Therapeutics, Inc. Common Stock	$3.07	-5.34×	2.16×	0×	-4.89×	-69.1%	0.0%	0.0%	0.0%	-40.5%	-42.9%	-18.6%	0.03×	0.56×	-530.37×	11.21×	0.0%	1	5.08	2	B-
CAPRCapricor Therapeutics, Inc.	$9.10	-12.77×	4.39×	0×	-10.7×	-20.2%	0.0%	0.0%	0.0%	-34.4%	-33.4%	-5.4%	0.06×	2.7×	-35.51×	9.01×	0.0%	2	0.16	2	C
CTNMContineum Therapeutics, Inc.	$10.02	-5.27×	1.21×	0×	-3.68×	-74.9%	0.0%	0.0%	0.0%	-23.0%	-25.3%	-17.5%	0.03×	0.99×	0×	27.5×	0.0%	2	16.76	2	C+
KYTXKyverna Therapeutics, Inc.	$5.08	-2.58×	1.79×	0×	-2.02×	-60.9%	0.0%	0.0%	0.0%	-69.4%	-65.0%	-36.9%	0.12×	0.6×	-347.29×	7.75×	0.0%	1	-0.9	2	C
LRMRLarimar Therapeutics, Inc.	$2.46	-1.68×	3.56×	0×	-1.19×	-55.3%	0.0%	0.0%	0.0%	-212.2%	-210.0%	-40.8%	0.05×	0.49×	0×	2.19×	0.0%	1	-2.84	2	C+
VNDAVanda Pharmaceuticals Inc.	$4.01	-2.36×	1.59×	2.41×	-3.53×	-130.5%	94.0%	-70.0%	-102.0%	-67.4%	-43.3%	-21.2%	0.04×	0.57×	0×	2.39×	0.0%	2	-1.81	2	C
Peer median	—	-2.58×	1.79×	0×	-3.53×	-60.9%	0.0%	0.0%	0.0%	-67.4%	-43.3%	-21.2%	0.05×	0.6×	0×	7.75×	0.0%	2	-0.9	2	—